Plus Therapeutics Presents Leptomeningeal Metastases Programs at 2024 SNO Annual Meeting in Houston, Texas
Company to Present Results from Phase 1 Clinical Trial of Rhenium (186Re) Obisbemeda for Leptomeningeal Metastases AUSTIN, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for CNS cancers, will be presenting data at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting in Houston, Texas….